Oral Cyclophosphamide for Patients With Metastatic Castration-Resistant Prostate Cancer in a Scenario of Limited Health Care Resources
PURPOSEPrior noncontemporary studies showed that oral cyclophosphamide is an active treatment of metastatic castration-resistant prostate cancer (mCRPC). However, cyclophosphamide is currently underutilized in routine clinical practice given the lack of survival benefit and the emergence of more eff...
Saved in:
Main Authors: | Diana del Cisne Pineda, Gabriel Berlingieri Polho, Yumi Ricucci Shinkado, Gustavo Alves Contado, Nathalia de Souza Crusoe, Vivian Naomi Horita, Joao Carlos Resende, Jamile Almeida Silva, Guilherme Fialho de Freitas, David Queiroz Muniz, Caio V. Suartz, Leopoldo Alves Ribeiro-Filho, Paulo M. Hoff, José Mauricio Mota |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society of Clinical Oncology
2025-01-01
|
Series: | JCO Global Oncology |
Online Access: | https://ascopubs.org/doi/10.1200/GO-24-00464 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cyclophosphamide: An Overview
by: Aditya Kumar Bubna
Published: (2025-01-01) -
Cyclophosphamide: An Alternative Treatment in Crohn’s Disease
by: Gilles Lapointe, et al.
Published: (1989-01-01) -
HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
by: Andrea Bacigalupo, et al.
Published: (2016-01-01) -
Effect of Age at Castration on Beef Calf Performance
by: Amie Imler, et al.
Published: (2013-03-01) -
Does the Method of Castration Affect Calf Performance?
by: Trey Warnock, et al.
Published: (2014-02-01)